An automated system that correlates histologic and mammographic results could refine radiologists' ability to detect breast cancer, according to a multicenter study published in the February issue of the American Journal of Roentgenology.Investigators
An automated system that correlates histologic and mammographic results could refine radiologists' ability to detect breast cancer, according to a multicenter study published in the February issue of the American Journal of Roentgenology.
Investigators from Stanford University and the University of California, San Francisco used a computer model to calculate breast disease probabilities based on Breast Imaging Reporting and Data System (BI-RADS) descriptors. They built the system by identifying in the literature 25 diseases of the breast - 11 malignant and 14 benign.
The researchers tested the model by correlating histologic results from 92 consecutive image-guided breast biopsies with their corresponding mammographic findings. They spotted incorrect pathologic diagnoses with 100% sensitivity and 91% specificity and achieved a sampling error rate of 1.1%, said principal investigator Dr. Elizabeth S. Burnside.
The system's automated oversight can help radiologists identify questionable cases and reduce the incidence of sampling errors not detected while reviewing biopsy or imaging results, according to Burnside, a radiologist formerly at UCSF and now with the University of Wisconsin. The Bayesian network can easily handle and structure data in a mammographic report to assess concordance automatically, providing routine oversight to the task of imaging-histologic correlation.
Out of 43 hierarchically organized descriptors making up BI-RADS, researchers excluded five to simplify their model. They skipped skin thickening, trabecular thickening, nipple retraction, skin retraction, and asymmetric breast tissue. These findings are either late signs of breast cancer or benign features rarely observed in the population of patients undergoing percutaneous biopsy.
The study showed several limitations. Researchers did not make distinctions among 14-gauge, 11-gauge, or excisional biopsies, mostly to determine if the system could truly represent the type of population involved in clinical practice. Histologic diagnoses recorded in the system, on the other hand, are broad categorizations of the descriptors used in pathologic reports.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.